Drug intelligence / Profile preview

donepezil + idalopirdine + memantine

Development stage: Discontinued
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

A combination of three drugs investigated for the treatment of moderate to severe Alzheimer's disease. Donepezil is an acetylcholinesterase inhibitor that prevents the breakdown of acetylcholine, improving nerve cell function in the brain. Memantine is an NMDA receptor antagonist that reduces the actions of chemicals in the brain contributing to Alzheimer's symptoms. Idalopirdine is a 5-HT6 receptor antagonist that was investigated as an adjunctive therapy. The triple combination was studied for potential synergistic effects on brain activity and cognition.

Targets

HTR6 (5-hydroxytryptamine receptor 6)NMDAR (Glutamate receptor ionotropic, NMDA)Acetylcholinesterase

Beyond the preview

Go deeper on donepezil + idalopirdine + memantine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + idalopirdine + memantine.

Explore the full profile